These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7669713)

  • 1. Paclitaxel-induced neuropathy.
    Postma TJ; Vermorken JB; Liefting AJ; Pinedo HM; Heimans JJ
    Ann Oncol; 1995 May; 6(5):489-94. PubMed ID: 7669713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
    van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
    Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
    Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
    J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel (Taxol) induces cumulative mild neurotoxicity.
    van Gerven JM; Moll JW; van den Bent MJ; Bontenbal M; van der Burg ME; Verweij J; Vecht CJ
    Eur J Cancer; 1994; 30A(8):1074-7. PubMed ID: 7654432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
    Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
    Forsyth PA; Balmaceda C; Peterson K; Seidman AD; Brasher P; DeAngelis LM
    J Neurooncol; 1997 Oct; 35(1):47-53. PubMed ID: 9266440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
    Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
    J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
    Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
    Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase I study with one-hour paclitaxel infusion.
    Mross K; Hauns B; Häring B; Bauknecht T; Meerpohl HG; Unger C; Maier-Lenz H
    Ann Oncol; 1998 May; 9(5):569-72. PubMed ID: 9653500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.
    Iñiguez C; Larrodé P; Mayordomo JI; González P; Adelantado S; Yubero A; Trés A; Morales F
    Neurology; 1998 Sep; 51(3):868-70. PubMed ID: 9748043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
    J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
    Pace A; Nisticò C; Cuppone F; Bria E; Galiè E; Graziano G; Natoli G; Sperduti I; Jandolo B; Calabretta F; Tomao S; Terzoli E
    Clin Breast Cancer; 2007 Apr; 7(7):550-4. PubMed ID: 17509163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
    Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
    Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.